Your Sorted CME/CE Activities

Conversations in HCV: Elimination and Treatment Challenges
Certified CME/CNE/CPE Activity
The national strategy for the elimination of HCV in the United States calls for a 90% reduction incidence of HCV and having 90% of those with HCV being treated. Significant strides have been achieved in simplifying HCV treatment regimens and improving SVR rates. Despite these advances, there are a number of challenging scenarios in HCV that require clinicians to become continually educated on the state-of-the-art approach to HCV management as well as safe and appropriate use of DAA regimens.

These Conversations in HCV will discuss the progress and barriers to achieving HCV elimination, challenging management issues in special patient populations, and strategies for HCV/HIV and HCV/HBV coinfection.
Review each video to claim AMA, ANCC, or ACPE credit/contact hour(s) after completion of the brief Post-Test/Evaluation.





Ask the Expert
CME Course Director  
Nancy Reau, MD Nancy Reau, MD, FAASLD, AGAF
Section Chief, Hepatology
Rush University Medical Center
Associate Director, Solid Organ Transplantation
Rush University Medical Center
 
Faculty Presenters  
Kimberly Brown, MD Kimberly Brown, MD, FAST, AGAF, FAASLD
Chief, Gastroenterology and Hepatology
Henry Ford Hospital
Detroit, MI
Robert S. Brown, Jr., MD, MPH Robert S. Brown, Jr., MD, MPH
Gladys and Roland Harriman Professor of Medicine
Clinical Chief, Division of Gastroenterology & Hepatology
Weill Cornell Medical College
New York, NY
Mark Sulkowski, MD Mark Sulkowski, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Medical Director, Viral Hepatitis Center
Johns Hopkins Hospital
Baltimore, MD
   

20
Supported by an independent educational grant from AbbVie
March 31, 2020
Clinical Conversation
6258
ConversationsInHCV.v2_WebBanner(1).gif
LiverDisease